Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | -97.32% | 0.00% | +16.67% |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Molecules
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 86 | 82-05-12 | |
J. Finkelstein
CEO | Chief Executive Officer | 72 | 83-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Finkelstein
CEO | Chief Executive Officer | 72 | 83-12-31 |
Founder | 86 | 82-05-12 | |
Joe McNay
BRD | Director/Board Member | 90 | 01-12-31 |
Mauro Bove
BRD | Director/Board Member | 69 | 03-12-31 |
R. Elsey
BRD | Director/Board Member | 71 | 10-08-31 |
Director/Board Member | 66 | 19-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,496,966 | 836,249 ( 55.86 %) | 0 | 55.86 % |
Company contact information
RegeneRx Biopharmaceuticals, Inc.
15245 Shady Grove Road Suite 470
20850, Rockville
+
http://www.regenerx.comSector
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.56% | 15.36B | |
-8.82% | 11.95B | |
-15.32% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- RGRX Stock
- Company RegeneRx Biopharmaceuticals, Inc.